1. Educational Experience
(1) 2015/09-2020/07 China Pharmaceutical University, Pharmaceutical Ph.D
(2) 2011/09-2015/07 China Pharmaceutical University, Pharmacy (National Education Base of Life Science and Technology) Bachelor
2. Working Experience
(1) 2022/06-Now School of Pharmacy, China Pharmaceutical University, Associate Professor.
(2) 2020/08-2022/06 School of Pharmacy, China Pharmaceutical University, Post-doctor.
1. Regulate and repair Alzheimer’s disease (AD) by natural nanoparticles like high-density lipoprotein, and develop novel nano drugs for AD prevention and treatment.
2. Explore stem cell transplantation therapy and engineering technology to reverse nerve damage in central system diseases.
3. Develop CRISPR/Cas targeted brain delivery system for glioma and other central malignant diseases, explore and optimize the postoperative management of glioma and improve the prognosis.
1. Research Projects
(1) National Natural Science Foundation of China (No. 82104097), 2022-2024, Host
(2) Natural Science Foundation of Jiangsu Province (No. BK20210426), 2021-2024, Host
(3) China Postdoctoral Science Foundation (No. 2020TQ0359), 2020-2022, Host
(4) China Postdoctoral Science Foundation (No. 2020M681790), 2020-2022, Host
(5) The post-doctoral daily support of Jiangsu Province, 2021-2022, Host
(6) The post-doctoral scientific support of Jiangsu Province, 2021-2022, Host
2. Academic Awards
(1) 2021, China Pharmaceutical University Colorcon Teaching Award, (1/1)
(2) 2020, Baxter China Outstanding Young Researchers First Prize, (1/1)
(3) 2019, American Association of Pharmaceutical Scientists Award for Best Abstract, (1/1)
(4) 2018, American Association of Pharmaceutical Scientists Award for Best Abstract, (1/1)
(5) 2018, American Association of Pharmaceutical Scientists Award for Travel Award, (1/1)
3. Representative Research Achievements
(1) Lipoprotein-Inspired Nanoscavenger for the Three-Pronged Modulation of Microglia-Derived Neuroinflammation in Alzheimer’s Disease Therapy, Nano Letters (2022, 22(6):2450-2460).
A Three-Pronged lipoprotein nanoscavenger was constructed to achieve a full-chain Alzheimer’s disease therapy in which the vector pHDL accelerates the clearance of Aβ by microglia cells, the drug curcumin inhibits microglia inflammation and siBACE1 gene silencing reduces neuronal Aβ production. The study was inspired by the high density lipoprotein level in the body to predict a lower risk of AD and based on the dominant biological structure of HDL blood-brain barrier penetration and Aβ affinity.
(2) “Drug-Carrier” Synergy Therapy for Amyloid-β Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly, Advanced Science (2022, 2106072).
Based on the disease pathologically oriented nano-drug design concept, the study divided high density lipoprotein active element into vector, optimized component compatibility and loaded drug methylene blue, constructed a “drug-carrier” synergy therapy, explored the synergistic therapy of carrier scavenging of Aβ and drug inhibition of phosphorylation Tau, and explored a new mode of AD prevention and treatment.
(3) Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy，J Control Release (2022, 345:38–61).
The review systematically combed the complex pathological mechanism of AD and deeply discussed the endogenous relationship of multi-target drugs, summarized the clinical research status and development trend of different target drugs and the latest progress of nanomaterials in the treatment of AD. This paper puts forward the concept and key points of the design of nanomaterials based on disease pathology and discusses how to design nanomaterials based on the pathological mechanism of AD to break through the current therapeutic dilemma of AD.
1. Zhang, H.1; Jiang, W.1; Zhao, Y.1; Song, T.; Xi, Y.; Han, G.; Jin, Y.; Song, M.; Bai, K.; Zhou, J.*; Ding, Y.*, Lipoprotein-Inspired Nanoscavenger for the Three-Pronged Modulation of Microglia-Derived Neuroinflammation in Alzheimer's Disease Therapy. Nano Lett 2022, 22 (6), 2450-2460. (IF: 12.262)
2. Han, G.1; Bai, K.1; Yang, X.; Sun, C.; Ji, Y.; Zhou, J.*; Zhang, H.*; Ding, Y.*, Drug-Carrier Synergy Therapy for Amyloid-beta Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly. Adv Sci. 2022, 9 (14), e2106072. (IF: 17.521)
3. Xi, Y.1; Chen, Y.1; Jin, Y.; Han, G.; Song, M.; Song, T.; Shi, Y.; Tao, L.; Huang, Z.; Zhou, J.*; Ding, Y.*; Zhang, H.*, Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy. J Control Release. 2022, 345, 38-61. (IF: 11.467)
4. Zhang, H.1; Jin, Y.1; Chi, C.1; Han, G.1; Jiang, W.1; Wang, Z.; Cheng, H.; Zhang, C.; Wang, G.; Sun, C.; Chen, Y.; Xi, Y.; Liu, M.; Gao, X.; Lin, X.; Lv, L.; Zhou, J.*; Ding, Y.*, Sponge particulates for biomedical applications: Biofunctionalization, multi-drug shielding, and theranostic applications. Biomaterials. 2021, 273, 120824. (IF: 15.304)
5. Zhang, H.1; Cheng, H.1; Han, Y.1; Jin, Y.; Wang, G.; Sun, C.; Jiang, W.; Han, G.; Sun, B.; Jiang, Z.; Yuan, Z.; Zhou, J.*; Ding, Y.*, Natural discoidal lipoproteins with tiny modification for tumor extracellular dissociation in antitumor chemoimmunotherapy. Biomaterials. 2021, 275, 120859. (IF: 15.304)
6. Jin, Y.1; Chifodya, K.1; Han, G.1; Jiang, W.; Chen, Y.; Shi, Y.; Xu, Q.; Xi, Y.; Wang, J.; Zhou, J.*; Zhang, H.*; Ding, Y.*, High-density lipoprotein in Alzheimer's disease: From potential biomarkers to therapeutics. J Control Release. 2021, 338, 56-70. (IF: 11.467)
7. Cheng, H.1; Zhang, H.1; Xu, G.; Peng, J.; Wang, Z.; Sun, B.; Aouameur, D.; Fan, Z.; Jiang, W.; Zhou, J.*; Ding, Y.*, A Combinative Assembly Strategy Inspired Reversibly Borate-Bridged Polymeric Micelles for Lesion-Specific Rapid Release of Anti-Coccidial Drugs. Nano-Micro Lett. 2020, 12 (1), 155. (IF: 16.419)
8. Zhang, H.; Zhao, Y.; Yu, M.; Zhao, Z.; Liu, P.; Cheng, H.; Ji, Y.; Jin, Y.; Sun, B.; Zhou, J.*; Ding, Y.*, Reassembly of native components with donepezil to execute dual-missions in Alzheimer's disease therapy. J Control Release. 2019, 296, 14-28. (IF: 11.467)
9. Dong, Q.1; Zhang, H.1; Han, Y.; Djamila, A.; Cheng, H.; Tang, Z.; Zhou, J.*; Ding, Y.*, Tumor environment differentiated nanodepot programmed for site-specific drug shuttling and combinative therapy on metastatic cancer. J Control Release. 2018, 283, 59-75. (IF: 11.467)
Jianping Zhou Professor
Yang Ding Professor
Huaqing Zhang Associate Professor
Hao Cheng Post-doctor
Ph.D candidate:
Guochen Han; Zhechen Fan; Taoxing Peng (Class of 2020)
Yi Jin; Linna Yu; Gang Wang; Yilong Xi; Shengyu Liu (Class of 2021)
Mingjie Song; Peihong Chen; Yi Wang; Jie Li (Class of 2022)
Master candidate:
Tingting Song; Yun Chen; Yang Shi; Feng Zhang; Jianye Ren; Xiaoyu Yang; Xiangze Zhang; Zhongsheng Ji; Wei Tian; Lingyu Lv; Zhen Cao; Yifei Jing; Shurong Shi; Lin Guo (Class of 2020)
Yuemei Gao; Min Zhou; Li Zhou; Yao Hu; Ningshu Lu; Shibeilei Shang; Kaiwen Bai; Zhangyi Miao; Shihao Wang; Man Yang (Class of 2021)
Qiaofei Du; Sulei Ge; Yifan Zhou; Hongying Yu; Zhenning Ye; Chuxing Cai; Xuezhe Duan; Tao Ji; Yining Li; Tianye Ling; Jia Qian; Haiying Su (Class of 2022)
